BioCentury | May 5, 2003
Finance

Ebb & Flow

...out its drug discovery infrastructure. In February 2002, the company acquired high throughput screening company PrimeCyte...
...see BioCentury, Feb. 11 & Feb. 4, 2002). Signature's PC4071 lead molecule, acquired in the PrimeCyte...
BioCentury | Mar 4, 2002
Finance

Ebb & Flow

...its drug discovery infrastructure. In the past month, the company acquired high throughput screening company PrimeCyte...
BioCentury | Feb 19, 2002
Company News

Oridigm management update

...Seattle, Wash. Business: Autoimmune/Inflammation, Chemistry Hired: Frederick Dechow as president and CEO, formerly CEO of PrimeCyte Inc. WIR...
BioCentury | Feb 11, 2002
Company News

PrimeCyte, Signature BioScience deal

...Signature completed its previously announced acquisition of PrimeCyte (see BioCentury, Jan. 14). The deal combines PrimeCyte’s...
...cell high throughput screening technology with Signature’s WaveScreen multipole coupling spectroscopy technology for drug discovery. PrimeCyte Inc....
BioCentury | Jan 14, 2002
Finance

2002 Financial Markets Preview: Repricing the venture space

...addition to getting PrimeCyte's Cytection primary cell high throughput screening technology, the deal also brings PrimeCyte's...
BioCentury | Jan 14, 2002
Company News

PrimeCyte, Signature deal

...Signature will acquire PrimeCyte in a deal that combines PrimeCyte's Cytection primary cell high throughput screening...
...WaveScreen multipole coupling spectroscopy technology for drug discovery. The deal also brings to Signature's pipeline PrimeCyte's...
...lead candidate, PC4071, which is in Phase II testing to treat ovarian cancer and sarcomas. PrimeCyte Inc....
BioCentury | Jan 8, 2002
Company News

Signature BioScience to acquire PrimeCyte

...Hayward, Calif.) will acquire oncology company PrimeCyte (Seattle, Wash.). Signature said the deal will combine PrimeCyte's...
...technology with Signature's WaveScreen multipole coupling spectroscopy technology for drug discovery. The deal also brings PrimeCyte's...
BioCentury | Dec 3, 2001
Company News

PPD, PrimeCyte deal

...PPDI made an equity investment in Primecyte through the purchase of preferred stock and warrants. Primecyte’s...
...uses primary human tumor cells to screen for effective compounds. PPD Inc. (PPDI), Wilmington, N.C. Primecyte Inc....
BioCentury | Nov 12, 2001
Clinical News

PC4071 regulatory update

...PrimeCyte received Orphan Drug designation from the FDA for PC4071 to treat soft tissue sarcomas. PrimeCyte Inc....
Items per page:
1 - 9 of 9
BioCentury | May 5, 2003
Finance

Ebb & Flow

...out its drug discovery infrastructure. In February 2002, the company acquired high throughput screening company PrimeCyte...
...see BioCentury, Feb. 11 & Feb. 4, 2002). Signature's PC4071 lead molecule, acquired in the PrimeCyte...
BioCentury | Mar 4, 2002
Finance

Ebb & Flow

...its drug discovery infrastructure. In the past month, the company acquired high throughput screening company PrimeCyte...
BioCentury | Feb 19, 2002
Company News

Oridigm management update

...Seattle, Wash. Business: Autoimmune/Inflammation, Chemistry Hired: Frederick Dechow as president and CEO, formerly CEO of PrimeCyte Inc. WIR...
BioCentury | Feb 11, 2002
Company News

PrimeCyte, Signature BioScience deal

...Signature completed its previously announced acquisition of PrimeCyte (see BioCentury, Jan. 14). The deal combines PrimeCyte’s...
...cell high throughput screening technology with Signature’s WaveScreen multipole coupling spectroscopy technology for drug discovery. PrimeCyte Inc....
BioCentury | Jan 14, 2002
Finance

2002 Financial Markets Preview: Repricing the venture space

...addition to getting PrimeCyte's Cytection primary cell high throughput screening technology, the deal also brings PrimeCyte's...
BioCentury | Jan 14, 2002
Company News

PrimeCyte, Signature deal

...Signature will acquire PrimeCyte in a deal that combines PrimeCyte's Cytection primary cell high throughput screening...
...WaveScreen multipole coupling spectroscopy technology for drug discovery. The deal also brings to Signature's pipeline PrimeCyte's...
...lead candidate, PC4071, which is in Phase II testing to treat ovarian cancer and sarcomas. PrimeCyte Inc....
BioCentury | Jan 8, 2002
Company News

Signature BioScience to acquire PrimeCyte

...Hayward, Calif.) will acquire oncology company PrimeCyte (Seattle, Wash.). Signature said the deal will combine PrimeCyte's...
...technology with Signature's WaveScreen multipole coupling spectroscopy technology for drug discovery. The deal also brings PrimeCyte's...
BioCentury | Dec 3, 2001
Company News

PPD, PrimeCyte deal

...PPDI made an equity investment in Primecyte through the purchase of preferred stock and warrants. Primecyte’s...
...uses primary human tumor cells to screen for effective compounds. PPD Inc. (PPDI), Wilmington, N.C. Primecyte Inc....
BioCentury | Nov 12, 2001
Clinical News

PC4071 regulatory update

...PrimeCyte received Orphan Drug designation from the FDA for PC4071 to treat soft tissue sarcomas. PrimeCyte Inc....
Items per page:
1 - 9 of 9